Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 12/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 11/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 9/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.43 |
| ▸ | CDK2 | P24941 | 6/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452648 | 0.86 | TNF (0.43) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL13110756 | 0.83 | TNF (0.49) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL1163165 | 0.79 | DYRK1A (0.49) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL3411320 | 0.78 | ALDH1A1 (0.44) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL16010635 | 0.78 | TNF (0.44) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL16554675 | 0.77 | TNF (0.50) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL31601848 | 0.75 | DYRK1A (0.51) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL23116158 | 0.75 | KDM4E (0.55) | TNFALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28741961 | 0.73 | TNF (0.47) | TNFDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL9216298 | 0.73 | TNF (0.53) | TNFDYRK1ADYRK2DYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOT2 | TNF 2607/4885DYRK1A 639/4885DYRK2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.